Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Carparts.Com Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.32 (market cap $8.04B), while Carparts.Com Inc trades at $5.76 (market cap $47.74M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 168.4× Carparts.Com Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PRTS | |
|---|---|---|
Market Cap | $8.04B | $47.74M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $11.40 |
52-Week Low | $241.71 | $3.88 |
Enterprise Value | $7.85B | $62.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
CarParts.com (PRTS) trades at $5.66, down 3.58% today, with a bearish technical signal despite recent positive developments including Nasdaq compliance and a $25 million credit facility. The company shows improving operational metrics with three consecutive earnings beats, though it remains unprofitable with negative margins and cash flow. Valuation metrics appear attractive with P/S of 0.07 and P/B of 0.77, but fundamental challenges persist.
While analyst sentiment is positive (60% buy ratings) and recent corporate actions provide stability, PRTS faces significant execution risks amid declining revenue and persistent losses. The stock offers speculative appeal for turnaround investors but requires careful monitoring of cash burn and profitability improvements. Near-term catalysts include Q2 2026 earnings results expected at -$0.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
